Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.9250
+0.0423 (4.79%)
At close: Nov 26, 2025, 4:00 PM EST
0.8854
-0.0396 (-4.28%)
After-hours: Nov 26, 2025, 7:59 PM EST
Salarius Pharmaceuticals Employees
The last reported number of employees for Salarius Pharmaceuticals was 2.
Employees
2
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,502,379
Market Cap
5.42M
No historical employees data available.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLRX News
- 8 days ago - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewsWire
- 14 days ago - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewsWire
- 16 days ago - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - PRNewsWire
- 6 weeks ago - Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard - GlobeNewsWire
- 5 months ago - Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewsWire